nafamostat has been researched along with Hepatitis in 1 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Hepatitis: INFLAMMATION of the LIVER.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nakae, H | 1 |
| Tajimi, K | 1 |
1 other study available for nafamostat and Hepatitis
| Article | Year |
|---|---|
Correlation between serum nafamostat mesilate and activated coagulation time during continuous hemodiafiltration.
Topics: Acute Disease; Anticoagulants; Benzamidines; Diatomaceous Earth; Female; Guanidines; Hemodiafiltrati | 2005 |